Advertisement

Is It Practical to Develop a Class III Antiarrhythmic Agent?

  • H. P. K. Agersborg
  • J. Latts
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 100)

Abstract

In addressing the question of whether it is practical to develop a Class III antiarrhythmic agent, we confront not only the realities of drug development in the pharmaceutical industry but also the regulatory requirements of the Food and Drug Administration (FDA). To demonstrate the issues involved in a pharmaceutical company’s decision to develop a new drug, we provide a brief overview of the context in which drug development decisions are commonly made and then examine a Class III agent as an example of that process.

Keywords

Ventricular Arrhythmia Chemical Entity Antiarrhythmic Agent Developmental Cost Therapeutic Utility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • H. P. K. Agersborg
    • 1
  • J. Latts
    • 1
  1. 1.Wyeth-Ayerst ResearchRadnorUSA

Personalised recommendations